Our findings indicate that miR-125a-3p is capable of inducing a shift in the involvement of the ErbB2 pathway in the basal-like subtype of breast cancer, thereby sensitizing the cells to anti-HER2 therapies. This evidence concerns the gene ERBB2 and breast carcinoma.